Literature DB >> 33759783

The ABCs of the atypical Fam20 secretory pathway kinases.

Carolyn A Worby1, Joshua E Mayfield1, Adam J Pollak1, Jack E Dixon2, Sourav Banerjee3.   

Abstract

The study of extracellular phosphorylation was initiated in late 19th century when the secreted milk protein, casein, and egg-yolk protein, phosvitin, were shown to be phosphorylated. However, it took more than a century to identify Fam20C, which phosphorylates both casein and phosvitin under physiological conditions. This kinase, along with its family members Fam20A and Fam20B, defined a new family with altered amino acid sequences highly atypical from the canonical 540 kinases comprising the kinome. Fam20B is a glycan kinase that phosphorylates xylose residues and triggers peptidoglycan biosynthesis, a role conserved from sponges to human. The protein kinase, Fam20C, conserved from nematodes to humans, phosphorylates well over 100 substrates in the secretory pathway with overall functions postulated to encompass endoplasmic reticulum homeostasis, nutrition, cardiac function, coagulation, and biomineralization. The preferred phosphorylation motif of Fam20C is SxE/pS, and structural studies revealed that related member Fam20A allosterically activates Fam20C by forming a heterodimeric/tetrameric complex. Fam20A, a pseudokinase, is observed only in vertebrates. Loss-of-function genetic alterations in the Fam20 family lead to human diseases such as amelogenesis imperfecta, nephrocalcinosis, lethal and nonlethal forms of Raine syndrome with major skeletal defects, and altered phosphate homeostasis. Together, these three members of the Fam20 family modulate a diverse network of secretory pathway components playing crucial roles in health and disease. The overarching theme of this review is to highlight the progress that has been made in the emerging field of extracellular phosphorylation and the key roles secretory pathway kinases play in an ever-expanding number of cellular processes.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Golgi; biomineralization; endoplasmic reticulum (ER); enzyme mutation; enzyme structure; extracellular matrix; phosphorylation; secretion; signal transduction

Mesh:

Substances:

Year:  2021        PMID: 33759783      PMCID: PMC7948968          DOI: 10.1016/j.jbc.2021.100267

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  157 in total

Review 1.  The protein kinase complement of the human genome.

Authors:  G Manning; D B Whyte; R Martinez; T Hunter; S Sudarsanam
Journal:  Science       Date:  2002-12-06       Impact factor: 47.728

2.  Enamel renal syndrome: A novel homozygous FAM20A founder mutation in 5 new Brazilian families.

Authors:  Mauricio Rocha Dourado; Cássio Roberto Rocha Dos Santos; Simona Dumitriu; Daniela Iancu; Saleh Albanyan; Robert Kleta; Ricardo D Coletta; Ana Terezinha Marques Mesquita
Journal:  Eur J Med Genet       Date:  2018-10-28       Impact factor: 2.708

3.  Secretory kinase Fam20C tunes endoplasmic reticulum redox state via phosphorylation of Ero1α.

Authors:  Jianchao Zhang; Qinyu Zhu; Xi'e Wang; Jiaojiao Yu; Xinxin Chen; Jifeng Wang; Xi Wang; Junyu Xiao; Chih-Chen Wang; Lei Wang
Journal:  EMBO J       Date:  2018-06-01       Impact factor: 11.598

4.  Complex phenotypes associated with STIM1 mutations in both coiled coil and EF-hand domains.

Authors:  Elizabeth Harris; Umar Burki; Chiara Marini-Bettolo; Marcella Neri; Chiara Scotton; Judith Hudson; Marta Bertoli; Teresinha Evangelista; Bas Vroling; Tuomo Polvikoski; Mark Roberts; Ana Töpf; Kate Bushby; Daniel McArthur; Hanns Lochmüller; Alessandra Ferlini; Volker Straub; Rita Barresi
Journal:  Neuromuscul Disord       Date:  2017-05-04       Impact factor: 4.296

5.  Comparison of structures of various human fibrinogens and a derivative thereof by a study of the kinetics of release of fibrinopeptides.

Authors:  L S Hanna; H A Scheraga; C W Francis; V J Marder
Journal:  Biochemistry       Date:  1984-09-25       Impact factor: 3.162

6.  Human fibrinogen heterogeneity. A study of limited fibrinogen degradation.

Authors:  E Regañón; V Vila; J Aznar; B Laiz
Journal:  Clin Chim Acta       Date:  1989-09-15       Impact factor: 3.786

7.  Prevalence of chronic kidney disease in the United States.

Authors:  Josef Coresh; Elizabeth Selvin; Lesley A Stevens; Jane Manzi; John W Kusek; Paul Eggers; Frederick Van Lente; Andrew S Levey
Journal:  JAMA       Date:  2007-11-07       Impact factor: 56.272

8.  EXTL2, a member of the EXT family of tumor suppressors, controls glycosaminoglycan biosynthesis in a xylose kinase-dependent manner.

Authors:  Satomi Nadanaka; Shaobo Zhou; Shoji Kagiyama; Naoko Shoji; Kazuyuki Sugahara; Kazushi Sugihara; Masahide Asano; Hiroshi Kitagawa
Journal:  J Biol Chem       Date:  2013-02-10       Impact factor: 5.157

9.  In vitro phosphorylation of von Willebrand factor by FAM20c enhances its ability to support platelet adhesion.

Authors:  Qi Da; Hyojeong Han; Christian Valladolid; María Fernández; Tanvir Khatlani; Subhashree Pradhan; Jennifer Nolasco; Risë K Matsunami; David A Engler; Miguel A Cruz; K Vinod Vijayan
Journal:  J Thromb Haemost       Date:  2019-04-05       Impact factor: 5.824

10.  Further evidence for causal FAM20A mutations and first case of amelogenesis imperfecta and gingival hyperplasia syndrome in Morocco: a case report.

Authors:  Imane Cherkaoui Jaouad; Mustapha El Alloussi; Siham Chafai El Alaoui; Fatima Zahra Laarabi; Jaber Lyahyai; Abdelaziz Sefiani
Journal:  BMC Oral Health       Date:  2015-01-30       Impact factor: 2.757

View more
  2 in total

Review 1.  Looking lively: emerging principles of pseudokinase signaling.

Authors:  Joshua B Sheetz; Mark A Lemmon
Journal:  Trends Biochem Sci       Date:  2022-05-16       Impact factor: 14.264

Review 2.  Fam20C in Human Diseases: Emerging Biological Functions and Therapeutic Implications.

Authors:  Rongsheng Xu; Huidan Tan; Jiahui Zhang; Zhaoxin Yuan; Qiang Xie; Lan Zhang
Journal:  Front Mol Biosci       Date:  2021-12-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.